Great da­ta! Huge po­ten­tial! (Too bad it failed the pri­ma­ry end­point)

It’s not un­usu­al for a biotech to cher­ry pick the most promis­ing bits of da­ta from a clin­i­cal study and lead with its best re­sults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.